

**Supplementary Figure S1.** Susceptibility testing obtained using Etest<sup>®</sup> method for aztreonam in combination with ceftazidime-avibactam, ceftolozane-tazobactam and amoxicillin clavulanate on NDM-1-producing *E. coli* isolate. **A.** MICs of aztreonam (ATM), ceftazidime-avibactam (CZA), ceftolozane-tazobactam (C/T) and amoxicillin-clavulanate (AMC) on Mueller-Hinton agar. **B.** MICs of aztreonam/ceftazidime-avibactam, aztreonam/ceftolozane-tazobactam and aztreonam/amoxicillin-clavulanate. The combination was tested by first applying on MH agar the Etest<sup>®</sup> containing the inhibitor (ceftazidime-avibactam, ceftolozane-tazobactam or amoxicillin-clavulanate), removed after 10 min, and then applying the aztreonam Etest<sup>®</sup>. **C.** MICs of aztreonam on MH agar supplemented with 4 mg/L of tazobactam. **D.** MICs of aztreonam on MH agar supplemented with 2 mg/L of clavulanate.

